Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.

Sunscreen is not locally produced in Zambia, making it inaccessible to many - especially those in rural areas where individuals with albinism are particularly vulnerable to the harsh effects of ...